{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:33:09Z","timestamp":1767850389980,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Bhutan is committed to eliminating hepatitis B and hepatitis C, though recent baseline estimates of disease burden in the general population are unknown. In 2017, we carried out a biomarker survey in the general population to estimate the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) biomarkers to evaluate the impact of immunization and guide further efforts.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In 2017, a cross-sectional, population-based, three-stage cluster survey was undertaken of the general population (1\u201317 and 20+ years of age). We visited households, collected blood specimens and administered a standard questionnaire. Specimens were collected for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) testing. We calculated prevalence of infection and selected characteristics, along with confidence intervals (CIs).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of 1372 individuals approached, 1358 (99%) participated. Of those, 1321 (97%) had a specimen tested for HBsAg, and among 1173 enrolled individuals 5\u2009years of age or older, 1150 (98%) individuals were tested for anti-HCV. The prevalence of HBsAg was 2.0% in 775 persons 20\u2009years of age or older (95% CI: 1.0\u20134.0) and 0.5% in 546 persons 1\u201317\u2009years of age (95% CI: 0.1\u20131.8). The prevalence of anti-HCV was 0.3% (95% CI: 0.1\u20130.8) among persons \u22655\u2009years.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Universal hepatitis B immunization of infants has resulted in a low prevalence of chronic HBV infection in persons 1\u201317\u2009years of age and the prevalence of anti-HCV is low among persons aged \u22655\u2009years. Efforts should continue to reach high coverage of the timely birth dose along with completion of the hepatitis B vaccine series. To reduce the chronic liver disease burden among adults, HBV and HCV testing and treatment as indicated might be restricted to pregnant women, blood donors, individuals with chronic liver diseases, and other groups with history of high-risk exposures.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05176-3","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T12:03:48Z","timestamp":1594209828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of HBV and HCV infections, Bhutan, 2017: Progress and next steps"],"prefix":"10.1186","volume":"20","author":[{"given":"N.","family":"Tshering","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. P.","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Wangchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wangdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Khandu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pelden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nogareda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-6794","authenticated-orcid":false,"given":"Y. J. F.","family":"Hutin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Wannemuehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. B.","family":"Rewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wangchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"5176_CR1","volume-title":"Global hepatitis report","author":"WHO","year":"2017","unstructured":"WHO. Global hepatitis report, 2017. Available at http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ (Accessed 19 June 2017).."},{"key":"5176_CR2","unstructured":"WHO. Draft global health sector strategies Viral hepatitis, 2016\u20132021. Report by the Secretariat. Agenda item A69\/32. Available http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA69\/A69_32-en.pdf?ua=1 (Accessed 21 June 2016)."},{"key":"5176_CR3","unstructured":"WHO. Technical considerations and case definitions to improve surveillance for viral hepatitis Surveillance document. Tech Rep. 2016; ISBN ISBN 978 92 4 154954 . Available at http:\/\/apps.who.int\/iris\/bitstream\/10665\/204501\/1\/9789241549547_eng.pdf?ua=1 (Accessed 21 June 2016)."},{"key":"5176_CR4","unstructured":"WHO. Monitoring and evaluation for viral hepatitis B and C: Recommended indicators and framework. Tech Rep. 2016; ISBN 978 92 4 151028 8. Available at http:\/\/apps.who.int\/iris\/bitstream\/10665\/204790\/1\/9789241510288_eng.pdf (Accessed 21 June 2016)."},{"key":"5176_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0923-2516(97)89894-9","volume":"148","author":"G Da Villa","year":"1997","unstructured":"Da Villa G, Andjaparidze A, Cauletti M, Franco E, Roggendorf M, Sepe A, Zaratti L. Viral hepatitis in the Bhutanese population: preliminary results of a seroepidemiological investigation. Res Virol. 1997;148:115\u20137.","journal-title":"Res Virol"},{"key":"5176_CR6","unstructured":"Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017 (http:\/\/www.who.int\/hepatitis\/publications\/guidelines-hepatitis-c-b-testing\/en\/, Accessed 19 Mar 2017)."},{"issue":"27","key":"5176_CR7","first-page":"369","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Hepatitis B vaccines: WHO position paper \u2013 July 2017. Wkly Epidemiol Rec. 2017;92(27):369\u201392 PMID: 28685564.","journal-title":"Wkly Epidemiol Rec"},{"key":"5176_CR8","unstructured":"Guidance for organizing external quality assessment schemes for HIV serological testing. Geneva: UNAIDS; 1996 [UNAIDS\/96.5] (http:\/\/www.who.int\/diagnostics_laboratory\/quality\/en\/EQAS96.pdf, Accessed 4 Dec 2015)."},{"key":"5176_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2471\/BLT.18.215210","volume":"96","author":"Y Hutin","year":"2018","unstructured":"Hutin Y, Desai S, Bulterys M. Preventing hepatitis B virus infection: milestones and targets. Bull World Health Organ. 2018;96:443\u2013443A.","journal-title":"Bull World Health Organ"},{"key":"5176_CR10","volume-title":"Monitoring health for the SDGs, sustainable development goals","author":"World health statistics 2016","year":"2016","unstructured":"World health statistics 2016. Monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization; 2016. (http:\/\/apps.who.int\/iris\/bitstream\/10665\/206498\/1\/9789241565264_eng.pdf?ua=1, Accessed 10 Mar 2017)."},{"key":"5176_CR11","volume-title":"Guidelines for verification of achievement of hepatitis B control target through immunization in the WHO South-East Asia Region","author":"WHO","year":"2019","unstructured":"WHO, 2019. Guidelines for verification of achievement of hepatitis B control target through immunization in the WHO South-East Asia Region. Available at: http:\/\/www.searo.who.int\/entity\/immunization\/highlights\/verification-guidelines.pdf (Accessed: 5 Dec 2019)."},{"key":"5176_CR12","doi-asserted-by":"publisher","unstructured":"P\u00e9pin J, Abou Chakra CN, P\u00e9pin E, Nault V, Valiquette L. Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010. PLoS One. 2014;9(6):e99677. https:\/\/doi.org\/10.1371\/journal.pone.0099677.","DOI":"10.1371\/journal.pone.0099677"},{"key":"5176_CR13","doi-asserted-by":"publisher","unstructured":"Bixler D, Zhong Y, Ly KN, Moorman AC, Spradling PR, Teshale EH, Rupp LLB, Gordon SC, Boscarino JA, Schmidt MA, Daida YG, Holmberg SD, CHeCS Investigators. Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2018. https:\/\/doi.org\/10.1093\/cid\/ciy598 [Epub ahead of print].","DOI":"10.1093\/cid\/ciy598"},{"key":"5176_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2016","unstructured":"Blach S, Zeuzem S, Manns M. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2016;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"suppl_1","key":"5176_CR15","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1093\/cid\/cis368","volume":"55","author":"S Kamili","year":"2012","unstructured":"Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for Hepatitis C virus infection. Clin Infect Dis. 2012;55(suppl_1):S43\u20138. https:\/\/doi.org\/10.1093\/cid\/cis368.","journal-title":"Clin Infect Dis"},{"key":"5176_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000186940","volume":"61","author":"L Mazzotta","year":"1992","unstructured":"Mazzotta L, Landucci G, Pfanner L, Carlini A, Angelini D, Giusti R, Antonelli A. Comparison between first and second generation tests to determine the frequency of anti-HCV antibodies in uremic patients in replacement dialytic therapy. Nephron. 1992;61:354\u20135.","journal-title":"Nephron"},{"key":"5176_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/0973-6247.126683","volume":"8","author":"E Gupta","year":"2014","unstructured":"Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci. 2014;8:19\u201325.","journal-title":"Asian J Transfus Sci"},{"issue":"Suppl 1","key":"5176_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jvh.12350","volume":"2","author":"V Saraswat","year":"2015","unstructured":"Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries. J Viral Hepat. 2015;2(Suppl 1):6\u201325.","journal-title":"J Viral Hepat"},{"key":"5176_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","volume":"1","author":"M Thursz","year":"2014","unstructured":"Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;1:28\u201335. https:\/\/doi.org\/10.1038\/nrgastro.2013.179 Epub 2013 Oct 1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5176_CR20","unstructured":"Regional framework for the triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific 2018\u20132030. WPR\/RC68\/7. Geneva: World Health Organization; 2018. Available from: http:\/\/www.wpro.who.int\/about\/regional_committee\/68\/documents\/wpr_rc68_7_annex_hiv_hepa_syphilis.pdf?ua=1&ua=1 [cited: 2018 May 23]."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05176-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05176-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05176-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:07:36Z","timestamp":1625699256000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05176-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5176"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05176-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"18 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Research & Ethical Board of Health, Bhutan, and the WHO Research Ethics Review Committee approved the survey protocol after the necessary amendments (Bhutan: REBH\/Approval\/2017\/008; WHO: ERC.0002874). This activity was reviewed in accordance with CDC human research protections procedures and was determined to be nonresearch, programme evaluation. Participants provided written consent for themselves. For children and adolescents 0\u201318\u2009years of age, parents or guardians provided written consent. Adolescents 12\u201318\u2009years of age provided written assent in addition to consent from parents \/ guardians.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"485"}}